METHODS:
We collected social, clinical and demographic characteristics and p16 protein status (p16-positive or p16-negative, using this immunohistochemistry variable as a surrogate marker of HPV status) for 3643 patients with oropharyngeal cancer diagnosed between 2000 and 2012 at comprehensive cancer centres in British Columbia (6 centres), Edmonton, Calgary, Toronto and Halifax. We used receiver operating characteristic curves and multiple imputation to estimate the p16 status for missing values. We chose a best-imputation probability cut point on the basis of accuracy in samples with known p16 status and through an independent relation between p16 status and overall survival. We used logistic and Cox proportional hazard regression.
RESULTS:
We found no temporal changes in p16-positive status initially, but there was significant selection bias, with p16 testing significantly more likely to be performed in males, lifetime never-smokers, patients with tonsillar or base-of-tongue tumours and those with nodal involvement (p < 0.05 for each variable). We used the following variables associated with p16-positive status for multiple imputation: male sex, tonsillar or base-of-tongue tumours, smaller tumours, nodal involvement, less smoking and lower alcohol consumption (p < 0.05 for each variable). Using sensitivity analyses, we showed that different imputation probability cut points for p16-positive status each identified a rise from 2000 to 2012, with the best-probability cut point identifying an increase from 47.3% in 2000 to 73.7% in 2012 (p < 0.001).
Data collection
We developed a single prospective, electronic database with an associated data dictionary, based on an existing database, 1 to allow all centres to capture information uniformly. We reviewed electronic medical records and data from institutional registries to obtain clinical and demographic characteristics: age at diagnosis, sex, marital status, body mass index, year of diagnosis, anatomic subsite, clinical staging, primary treatment, smoking status and alcohol consumption (as defined previously 1 ). The frequency of missing data is presented in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/ cmaj.161379/-/DC1).
p16 protein immunohistochemistry was used as a surrogate for HPV status, and results were dichotomized as p16-positive or p16-negative. [12] [13] [14] [15] Details on p16 testing can be found in Appendix 2 (available at www.cmaj.ca/lookup/suppl/doi :10.1503/cmaj.161379/-/DC1). p16 immunohistochemistry is a validated method to measure HPV status in oropharyngeal cancer. 12, 13, 16 
Statistical analysis
We used multivariable logistic regression to determine which factors were associated with p16 testing (tested v. untested) and p16 status among those tested (p16-positive v. p16-negative); these factors would form the basis of a predictive model used as a first step in imputation. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) for each factor. We then developed a predictive model based on the factors associated with p16 status, in preparation for multiple imputation of missing p16 data. We assessed the ability of the logistic regression model to predict p16 status using receiver operating characteristic curves, and compared areas under the curve between models using the C statistic (with 95% CI).
We performed overall survival analyses using Cox proportional hazard regression, presented with hazard ratios (HRs) and Kaplan-Meier plots. All multivariable models included the following covariables unless otherwise specified: age at diagnosis, sex, anatomic subsite (tonsil, base of tongue, other), tumour classification (T1-T4), nodal classification (N0-N3), smoking status (current, former, never), smoking pack-years and alcohol consumption (none/light, moderate/heavy). We stratified the data by the city or province of diagnosis, where appropriate.
Multiple imputation
Because we did not wish to limit our analysis to only those patients with results from HPV testing, we used multiple imputation to derive HPV status for patients with missing test results. Multiple imputation was conducted using the variables that resulted in the best predictive model for p16 status (using the C statistics described above). Following 100 imputations, the number of times that each patient was classified as p16-positive was referred to as the probability of p16-positive status or Pr(p16+). To classify patients as p16-positive or p16-negative, we defined a cut point of Pr(p16+) using leaveone-out cross-validation and survival analyses (an overview of the method is presented in Appendix 3, available at www.cmaj. ca/lookup/suppl/doi:10.1503/cmaj.161379/-/DC1). The distribution of Pr(p16+) was categorized into quintiles (Q1-Q5), and overall survival was compared with patients whose p16 status was known. Data from patients with known p16 status (the leave-one-out validation subset, n = 1282) were used to assess the accuracy of various Pr(p16+) cut points (Appendix 4, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj .161379/-/DC1).
Time trends were determined using the year of diagnosis as the only predictor. We assessed overall survival by p16 status because we wanted to use survival characteristics as a method of externally assessing the appropriateness of our planned multiple imputation (i.e., because HPV status affects survival, imputed HPV status should affect survival in a similar fashion). The overall survival of patients with oropharyngeal cancer by p16 status was evaluated in the Toronto, Alberta (Edmonton and Calgary combined) and Halifax data sets, where reasonable proportions of patients' tumours underwent p16 testing.
Sensitivity analysis
Although imputation would allow generation of the change in the proportion of p16-positive patients over time with less missingness bias, assumptions associated with multiple imputation meant additional sensitivity analyses were necessary. We evaluated the sensitivity of time trends to differences in how p16 status was defined. The Pr(p16+) was plotted over time as both a continuous probability and as a proportion when patients were classified (dichotomized) with 85% sensitivity. We performed further analyses stratifying by province. These statistical procedures, as well as those described above, were performed using SAS version 9.4 (SAS Institute Inc.).
Ethics approval
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Results

Patient population
Of 3643 patients with oropharyngeal cancer, the mean follow-up time was 2.6 (standard deviation 2.3) years. Although the various centres each contributed data for a different period between 2000 and 2012, patients with oropharyngeal cancer had similar characteristics across centres (Table 1) . Data from the 2 Alberta centres, which together covered the whole province, were combined for some of the subsequent analyses.
p16 testing and testing bias over time Despite routine testing in Halifax after 2009, p16 testing was unavailable for many patients; in these patients, the diagnosis was made from a fine-needle aspirate, which is not suitable for p16 staining. In univariable analyses, p16 testing was more likely to occur if patients were younger, were male, had tumours of the tonsil or base of the tongue, never smoked, had fewer pack-years, had less alcohol consumption and had some nodal involvement (p < 0.05 for all; see Appendix 6, available at www.cmaj.ca/ lookup/suppl/doi:10.1503/cmaj.161379/-/DC1). After adjustment, p16 testing was more likely to be performed in males, lifetime never-smokers, patients with tonsillar or base-oftongue tumours and those with nodal involvement. Over time, testing for p16 status became less discriminatory by sex and tumour stage, yet some residual bias may have remained (Appendix 5, panels B to F)
Using a complete-case analysis, we observed no temporal change in the proportion of p16-positive cases of oropharyngeal cancer (Appendix 7, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.161379/-/DC1). (8) 31 (9) 113 (7) 21 (18) Marital status n = 3320 n = 798 n = 401 n = 336 n = 1665 n = 120 
Modelling of p16 status
Given the documented testing bias, we attempted to assign p16 status to untested patients using multiple imputation. Factors associated with p16-positive status included being younger, being male, having a tonsillar or base-of-tongue tumour, having lower tumour stage and any nodal involvement, lack of smoking history and lower alcohol consumption (none/light). These analyses were restricted to the Toronto and Alberta subsets because of the model's sample size constraints ( Table 2 ). The ability of social, demographic and clinical factors to predict p16 status is presented in Figure 1 . The models that included age at diagnosis, sex, tumour classification, nodal classification, anatomic subsite, smoking status, smoking pack-years and alcohol consumption resulted in the highest C statistics (area under the curve). Neither body mass index (available only for Alberta patients) nor the Charlson comorbidity index improved the predictive ability of the models. Because of the small absolute number of patients from Halifax, a predictive model was not applied to this population.
Overall survival by p16 status p16-negative status was consistently associated with worse overall survival in all centres. Overall survival of patients with oropharyngeal cancer by p16 status for the Toronto, Alberta and Halifax data sets is presented in Figure 2 . According to a Cox propor- tional hazards regression model (stratified by province), the factors associated with poorer overall survival were older age, having a nontonsillar tumour, current smoking and having more advanced disease (Table 3) . Even after adjustment for these factors, patients with p16-negative tumours had twice the risk of death relative to p16-positive patients. Following multiple imputation, movement down each quintile of Pr(p16+), where Q5 was most likely to be p16-positive and Q1 was least likely to be p16-positive, was associated with an increase in mortality risk, with adjusted HR 1.58 (95% CI 1.51-1.66) per change in quintile ( Figure 3A) .
The optimal cut point (which maximized sensitivity and specificity) underestimated the p16-positive proportion of the validation subset (time 0; Appendix 8, available at www.cmaj.ca/lookup/ suppl/ doi:10.1503/cmaj.161379/-/DC1). However, lowering the Pr(p16+) cut point to yield a sensitivity of 85% resulted in nearly identical Kaplan-Meier plots between imputed and known p16 status in both the p16-positive and p16-negative strata, with 71% of the validation cohort being classified as p16-positive ( Figure 3B , time 0). This cut point corresponded to Pr(p16+) = 68.7% and was used to categorize patients as p16-positive or p16-negative.
Sensitivity analyses
Under the continuous definition, the Pr (p16+) The most robust rise in p16-positive oropharyngeal cancer was observed in Alberta, regardless of whether the Pr(p16+) was analyzed as a continuous variable ( Figure 4B ) or dichotomized with 85% sensitivity ( Figure 4C ). For comparison, alternative cut points are presented, including the optimal cut point and cut points resulting in 90% sensitivity, 90% specificity and 85% specificity ( Figure 4D) . Regardless of the cut point chosen, by 2012 (when the fewest patients had p16 status imputed), the propor- tion of p16-positive patients ranged from 71.0% (90% specificity) to 76.4% (continuous probability). Similar results were obtained in a sensitivity analysis that excluded British Columbia and Halifax (since most of the data from these 2 locations were imputed; Appendix 9, available at www.cmaj.ca/lookup/suppl/doi :10.1503/cmaj.161379/-/DC1). Thus, regardless of the cut points used for imputation of p16-positive status, there was a clinically significant rise in the incidence of p16-positive oropharyngeal cancer between 2000 and 2012. The rate of increase was greater for men than for women (Appendix 10, available at www.cmaj. ca/lookup/suppl/doi:10.1503/cmaj.161379/-/DC1).
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Interpretation
We found an increase in the incidence of p16-positive oropharyngeal cancers as a proportion of all oropharyngeal squamous cell cancers between 2000 and 2012 among patients managed at specialist surgical centres across Canada. The rate of increase was greater for men than for women.
Selection bias occurs in HPV testing, and estimating changes in the incidence of p16-positive oropharyngeal cancer over time has therefore been difficult. Before implementation of routine HPV testing, clinicians were aware that additional testing created a burden for clinical laboratories, and thus reserved testing for those most likely to have HPV positivity. Only as accumulating data have supported the clinical importance of HPV testing has routine testing been implemented in most (though not all) Can adian centres. By imputing missing HPV status and finding different ways to validate our findings (Appendix 3), we were able to estimate that the prevalence of HPV-positive oropharyngeal cancer in 5 Canadian centres rose from about 47% in 2000 to about 74% in 2012.
A recent systematic review reported that the rate of HPVpositive oropharyngeal cancer in North America plateaued at 65% from 2005 to 2014. 5 However, a study in London, Ontario, was restricted to patients with tonsillar cancer for whom a pathology specimen was available; 17 one study in Toronto included only 22 patients with oropharyngeal cancer; 18 other Toronto-based studies either took place before routine HPV testing 12 or focused on recurrent or metastatic disease; 19 and one study in Montréal analyzed patients with locally advanced cancer who were treated with primary chemoradiation and had a minimum 3-year follow-up. 20 A previous study of 1374 Ontario-based patients with oropharyngeal cancer suggested that 66% of cases were HPV-positive by 2010. 1 Given the limitations of these previous studies, a more comprehensive study across multiple Canadian centres was warranted.
HPV-positive oropharyngeal tumours differ from HPVnegative tumours with respect to etiology, histology and outcome, and we confirmed the need to test for HPV status as a routine diagnostic tool to differentiate these 2 distinct diseases. 21 Given the potential health policy implications of these timetrend results, such as HPV vaccination for both sexes, we suggest that routine testing be accompanied by either routine supplemental coding (e.g., ICD or other system) or cancer registry annotation, so that HPV-positive and HPV-negative cases can be easily and separately tracked in Canada. Efforts to standardize HPV testing methods also warrant consideration.
We used multiple imputation to estimate the probability of HPV-positive status, given the known associations of demographic, clinical and social habits with HPV status 22 (Appendix 3). Although some applications of multiple imputation are controversial, 23 we used strongly predictive variables in this imputation. 24 There is also evidence of the utility of imputation in data sets with large proportions of missing data. 25, 26 It is clear that without imputation, testing bias would affect the accuracy of results. 22, 27 We calibrated our results using survival data, which were external to the multiple imputation process, and performed leave-one-out internal cross-validation. Sensitivity analyses of the chosen cut point suggest a substantial rise over time. We caution against overinterpreting the absolute values for the proportion of cases that were HPV-positive in the earlier years; however, our findings regarding a rise in proportion of HPV-positive oropharyngeal tumours are consistent with widespread clinical experience. = 3643) , the imputed population (n = 2361) was compared with the population having known p16 status (n = 1282). For the imputed population, the probability of p16-positive status, or Pr(p16+), was categorized into quintiles (Q5 = most likely to be p16-positive, Q1 = least likely to be p16-positive) and compared with patients with known p16 status. (B) The analysis was restricted to the validation subset (patients with known p16 status only; n = 1282). Overall survival is presented by Pr(p16+) dichotomized with 85% sensitivity, where Pr(p16+) = 68.7%, and compared with the actual (i.e., tested) p16 status. , for all of Canada. Probability of p16-positive status, or Pr(p16+), was retained as a continuous probability or dichotomized with 85% sensitivity. The Pr(p16+) that resulted in 85% sensitivity was 68.7%. (B) Probability of patients deemed HPV-positive, as mean continuous probability Pr(p16+) over time, stratified by cancer centre. (C) Proportion of patients deemed HPV-positive using a cut point with 85% sensitivity, stratified by cancer centre. (D) Probability and proportion of patients deemed HPV-positive, for all of Canada. The Pr(p16+) over time is shown with various cut points, and the data for "continuous probability" from Figure 4A superimposed for comparison. The optimal cut point resulted in a sensitivity of 71% and a specificity of 81%.
Year of diagnosis
HPV or p16 protein testing. Accurate estimates of the incidence of HPV-positive oropharyngeal cancer are needed to inform future health policy.
